Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is set to release its earnings data before the market opens on Wednesday, November 1st. Analysts expect Agios Pharmaceuticals to post earnings of ($1.78) per share for the quarter.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same period last year, the firm posted ($1.47) EPS. Agios Pharmaceuticals’s quarterly revenue was up 62.1% compared to the same quarter last year. On average, analysts expect Agios Pharmaceuticals to post $-6.89 EPS for the current fiscal year and $-6.93 EPS for the next fiscal year.

Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 66.71 on Wednesday. The stock’s market cap is $3.23 billion. The stock has a 50 day moving average of $67.45 and a 200 day moving average of $57.38. Agios Pharmaceuticals, Inc. has a 12-month low of $39.24 and a 12-month high of $72.73.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/25/agios-pharmaceuticals-inc-agio-set-to-announce-earnings-on-wednesday.html.

A number of equities research analysts recently issued reports on the stock. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $83.00 price target (up previously from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Royal Bank Of Canada assumed coverage on shares of Agios Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target on the stock. SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 price target (up previously from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Finally, Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $75.20.

In other news, CEO David P. Schenkein sold 27,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the transaction, the chief executive officer now owns 3,000 shares in the company, valued at approximately $179,850. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $71.10, for a total value of $284,400.00. Following the transaction, the director now owns 84,394 shares in the company, valued at approximately $6,000,413.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 220,908 shares of company stock worth $14,628,238. Insiders own 10.55% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.